A Comparison of Dexmedetomidine, Nicardipine, and Labetalol to Induce Hypotensive Anesthesia and Their Effects on Surgeon Visibility, Blood Loss, Hemodynamic Parameters, Operation Time, and Adverse Events During Orthognathic Surgery

The overall objective of this double blinded, randomized controlled trial (RCT) is to compare specific outcomes of three medications (Dexmedetomidine, Nicardipine, and Labetalol) which are routinely used to lower blood pressure used during general anesthesia for orthognathic (jaw) surgery. The outcome measures for the study will be surgical field visibility, estimated blood loss, hemodynamic parameters, operation time, and adverse events.
The specific objectives of this study are to compare:
1. Dexmedetomidine, Nicardipine, and Labetalol's effect on the quality of the surgical field. (Primary Outcome)
2. Dexmedetomidine, Nicardipine, and Labetalol's effect on estimated blood loss.
3. Dexmedetomidine, Nicardipine, and Labetalol's effect on hemodynamic parameters including systolic blood pressure, mean arterial pressure, and heart rate.
4. Dexmedetomidine, Nicardipine, and Labetalol's effect on operation time.
5. Dexmedetomidine, Nicardipine, and Labetalol's effect on adverse events.
The investigators will evaluate healthy adult male and female patients who require jaw surgery at Boston Medical Center. The anticipated 90 participants will be randomized into three groups: ) A Labetalol group in which the patients receive hypotensive anesthesia with the aid of labetalol, 2) A Nicardipine group in which the patients receive hypotensive anesthesia with the aid of nicardipine, and 3) A Dexmedetomidine group in which the patients receive hypotensive anesthesia with the aid of dexmedetomidine.
The time it will take for each individual participant ranges from 1-3 months. This time includes the pre-operative visit, the surgical procedure, a 1-week post-operation visit, and then followed for 30 days post-operatively after which the patient's participation in the study will conclude.

开始日期2025-01-01

申办/合作机构

Boston Medical Center

NCT05551104

/ Recruiting临床3期IIT

Safest Choice of Antihypertensive Regimen for Postpartum Hypertension: A Randomized Control Trial (SCARPH)

The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.

开始日期2024-12-01

申办/合作机构

Loma Linda University

NCT06752863

/ Recruiting临床4期IIT

Comparative Study of Labetalol Infusion Versus Dexmedetomidine Infusion in Hypotensive Anesthesia in Ear, Nose and Throat Surgeries

this study aims to compare between the role of Labetalol infusion versus Dexmedetomidine infusion in hypotensive anesthesia in Ear, Nose and Throat surgeries.

开始日期2024-11-27

申办/合作机构

Ain Shams University

100 项与盐酸拉贝洛尔相关的临床结果

登录后查看更多信息

100 项与盐酸拉贝洛尔相关的转化医学

登录后查看更多信息

100 项与盐酸拉贝洛尔相关的专利（医药）

登录后查看更多信息

2,374

项与盐酸拉贝洛尔相关的文献（医药）

2025-01-15·The Journal of Maternal-Fetal & Neonatal Medicine

Race/ethnicity differences in response to acute antihypertensive treatment of peripartum severe hypertension

Article

作者: Kilpatrick, Sarah J. ; Pon, Fay F. ; Greene, Naomi H.

BACKGROUNDHypertensive disorders of pregnancy increase maternal morbidity, mortality, and long-term risk for cardiovascular disease. The rising incidence of chronic hypertension and preeclampsia disproportionately affects people of color. There is a paucity of published data examining differences in the effectiveness of acute antihypertensive agents between pregnant patients of different races/ethnicities. We aimed to determine if the effectiveness of acute antihypertensive agents for peripartum severe hypertension differs by race/ethnicity.METHODSA retrospective cohort study of patients with severe peripartum hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 110 mm Hg confirmed within 15 min) to determine whether the effectiveness of blood pressure control using nationally recommended medications (hydralazine, labetalol, nifedipine) differed by race/ethnicity. The primary outcome was reduction and maintenance of blood pressure to target ranges (140-150/90-100 mm Hg or below) for ≥4 h in each race/ethnicity group. Statistical tests included χ², Fisher's exact, analysis of variance, and multivariable logistic regression.RESULTSOf 729 patients receiving treatment for severe peripartum hypertension, all medications were effective (overall 86.4% efficacy) at controlling blood pressure. Labetalol was the most effective medication in White patients (93.0 vs. 74.7% for nifedipine and 86.5% for hydralazine, p < .001). No overall differences in medication effectiveness were found in Black, Asian, or LatinX patients. Black and Asian patients were more likely to experience >1 hypertensive episode [51.0 and 49.0%, respectively vs. 35.4% (White) and 40.0% (LatinX), p = .008].CONCLUSIONCurrently recommended therapies for severe peripartum hypertension are effective in controlling blood pressure for ≥4 h in patients of all race/ethnic groups. Labetalol was the most effective medication in White patients with no overall differences in medication effectiveness in Black, Asian, or LatinX patients.

2025-01-01·International Journal of Pharmaceutics

Hydrogel-forming microarray patches combined with powder-based reservoir for labetalol hydrochloride transdermal delivery

Article

作者: Detamornrat, Usanee ; Donnelly, Ryan F ; Larrañeta, Eneko ; Anjani, Qonita Kurnia

Hypertension is the most common pregnancy disorder and can lead to life-threatening conditions for both mother and fetus. However, managing this condition with oral and intravenous labetalol can be challenging, highlighting the need for alternative delivery methods. This study presents, for the first time, the development of novel powder-based reservoirs incorporated with hydrogel-forming microarray patches (MAPs) to facilitate the transdermal delivery of labetalol hydrochloride (HCl). A holder, created from poly(propylene) using a 3D printer, was designed to house labetalol HCl powder, which was then combined with hydrogel-forming MAPs. This novel system improved the insertion profile of MAPs into Parafilm® layers and excised full-thickness neonatal porcine skin, achieving up to 85 % of needle height penetration without compromising needle integrity (only 8 % height reduction after applying 32 N of force). The current holder design was able to load 50 mg of labetalol HCl and allowed for single or multiple injections of deionised water to dissolve the powder and facilitate permeation through dermatomed neonatal porcine skin in in vitro studies using a Franz cell setup. The results showed that this powder-based reservoir design delivered labetalol HCl more effectively over 24 h compared to directly compressed tablets. Additionally, poly(vinyl alcohol)/poly(vinyl pyrrolidone)/citric acid-based hydrogel-forming MAPs delivered more labetalol HCl than Gantrez® S-97/poly(ethylene glycol)-based MAPs (9 mg vs. 5 mg) in 24 h. This novel system holds promise for improving the delivery of compounds in a simple manner, though further design modifications for one-step application are needed.

2025-01-01·American Journal of Obstetrics & Gynecology MFM

Amlodipine versus nifedipine ER for the management of postpartum hypertension: a noninferiority randomized controlled trial

Article

作者: Lordo, Ross ; Pratt, Katelyn ; Carlson, Laura ; Self, Stella

BACKGROUNDPostpartum hypertension is an increasingly prevalent problem and optimizing its treatment is imperative in reducing maternal morbidity and improving long-term health outcomes. Despite this, data on treatment of postpartum hypertension is limited. While most available studies focus on labetalol and nifedipine ER, these medications are not frequently used for hypertension treatment in the non-obstetric setting. As we aim to establish best practices for managing postpartum hypertension, use of more commonly encountered antihypertensives should be evaluated.OBJECTIVETo evaluate the use of amlodipine for the treatment of postpartum hypertension, as assessed by postpartum length of stay.STUDY DESIGNIn a pragmatic, randomized controlled noninferiority trial, patients were assigned to amlodipine or nifedipine ER for treatment of postpartum hypertension. The primary outcome was time from delivery until discharge with a noninferiority limit of 24 hours. A sample size of 132 was needed to achieve 80% power with a 2-tailed alpha of 0.05. Intent-to-Treat and Per Protocol analyses were performed. Prespecified secondary outcomes included the need for additional antihypertensives, side effects, medication discontinuation, breastfeeding satisfaction, and readmission rate. A post-hoc analysis of time from medication initiation until hospital discharge was also performed.RESULTSFrom April 2021 to December 2022, 7618 patients were screened and 175 patients were randomized, with 132 meeting criteria for antihypertensive initiation. Baseline demographics were similar between groups. Amlodipine had a non-inferior length of stay compared to nifedipine ER (Intent-to-Treat Wilcoxon pseudo-median amlodipine=73.5 hours, nifedipine ER=72.0 hours, 95% CI -8.00 to 6.00). The remainder of analyses were performed only on the Per Protocol cohort. Time from medication initiation until hospital discharge was similar between groups (amlodipine=45.0 hours, nifedipine ER=45.5 hours, 95% CI -8.00 to 13.00). There were no differences in use of additional antihypertensives or patient-reported side effects or breastfeeding outcomes, but hypotension and tachycardia were less common with amlodipine use. Amlodipine was significantly less likely to be discontinued due to side effects (amlodipine n=0, nifedipine ER n=7 (10.1%), p=.02). Readmission rates were similar between groups.CONCLUSIONAmlodipine is noninferior to nifedipine ER for postpartum hypertension treatment, as defined by median length of postpartum stay. Rates of side effects were similar between groups, but there was a statistically significant difference in medication discontinuation rates.CLINICAL TRIAL REGISTRATIONClinicaltrials.gov, www.CLINICALTRIALSgov, NCT04790279.

项与盐酸拉贝洛尔相关的新闻（医药）

2025-01-12

·米内网

石四药厉害了！拿下34个重磅品种，2大注射剂涨逾100%，83个新品、2款1类新药冲刺

精彩内容在刚刚过去的2024年，石四药收获满满：拿下34个重磅品种，13个品种顺利过评，1款1类新药获批临床等。目前公司有115个品种过评或视同过评，17个品种在国采中标，17个品种备战新国采；在研产品中，83个品种以新分类申报在审，2款1类新药持续推进中。拿下34个重磅品种！2大注射剂涨逾100% 近日，石四药打响2025年产品获批“第一枪”，公司申报的4类仿制药富马酸伏诺拉生片获批生产并视同过评，该产品2023年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）的销售额超过6亿元。在刚刚过去的2024年，石四药有34个品种获批生产并视同过评，包括19个注射剂、12个口服常释剂型、2个干混悬剂以及1个缓释控释剂型。从治疗大类看，34个品种涵盖7个治疗大类，其中神经系统药物、心脑血管系统药物各有10个、消化系统及代谢药、血液和造血系统药物各有4个，全身用抗感染药物有3个等。 2024年石四药获批上市的品种来源：米内网中国申报进度（MED）数据库恩他卡朋双多巴片(Ⅱ)、卡左双多巴缓释片、利奈唑胺干混悬剂为国内首仿+首家过评。其中，在利奈唑胺上，石四药已完成从原料药到利奈唑胺葡萄糖注射液、利奈唑胺氯化钠注射液、利奈唑胺干混悬剂等主流剂型一体化布局。在儿童适用的干混悬剂型上，公司已有阿奇霉素干混悬剂、磷酸奥司他韦干混悬剂、司替戊醇干混悬剂、头孢呋辛酯干混悬剂、利奈唑胺干混悬剂等多个品种获批上市。此外，钠钾镁钙注射用浓溶液、脂肪乳(10%)/氨基酸(15)/葡萄糖(20%)注射液、甲磺酸倍他司汀片、盐酸艾司洛尔氯化钠注射液、比索洛尔氨氯地平片等为国产第2家获批；地拉罗司分散片、复方醋酸钠葡萄糖注射液、环丝氨酸胶囊、依托咪酯中/长链脂肪乳注射液、恩他卡朋片、头孢呋辛酯干混悬剂、醋酸钠林格葡萄糖注射液等国产第3家获批等。米内网数据显示，近年来，石四药获批品种数呈井喷式增长，2022年以前获批品种数仅为个位数，2022年突破两位数至14个，2023年超过20个至26个，2024年再创新高，获批品种数达34个。 2018-2024年石四药品种获批情况（以产品名计）来源：米内网中国申报进度（MED）数据库部分新上市品种市场表现亮眼，如2018及2022年获批的盐酸莫西沙星氯化钠注射液、左氧氟沙星氯化钠注射液等，2024上半年在中国公立医疗机构终端的销售额增速均超过100%。 115个过评品种亮眼，17个品种备战新国采截至目前，石四药已有115个品种过评或视同过评，其中有16个品种为国内首家过评，甲磺酸倍他司汀片、己酮可可碱缓释片、卡左双多巴缓释片、司替戊醇干混悬剂、恩他卡朋双多巴片(Ⅱ)等为独家过评。石四药已过评品种注：带*为首家或独家过评来源：米内网一致性评价进度数据库从治疗领域看，115个品种涵盖11个治疗大类，集中在全身用抗感染药物（25个）、血液和造血系统药物（24个）、神经系统药物（22个）、心脑血管系统药物（20个）等。在国家开展的八批九轮化药集采中，石四药累计有17个品种中选。目前公司已过评且暂未纳入国采的品种还有40余个，其中有17个已满足7家及以上的充分竞争条件。石四药过评但未集采且已满足7家及以上条件的品种注：低于1亿元用-代表来源：米内网综合数据库 17个药品2023年在中国公立医疗机构终端的销售额合计超过100亿元，其中达格列净口服常释剂型接近40亿元，低钙腹膜透析液(乳酸盐-G1.5%)、腹膜透析液(乳酸盐-G1.5%)均超过15亿元。富马酸伏诺拉生片、盐酸去氧肾上腺素注射液、注射用氯诺昔康、尼可地尔片、多巴丝肼片、马来酸氟伏沙明片、依托咪酯中/长链脂肪乳注射液、达格列净片等为石四药2024年后新获批上市品种；腹膜透析液(乳酸盐-G4.25%)、低钙腹膜透析液(乳酸盐-G2.5%)、低钙腹膜透析液(乳酸盐-G1.5%)、腹膜透析液(乳酸盐-G2.5%)、腹膜透析液(乳酸盐-G1.5%)等于2019年获批，目前公司在上述品种所占市场份额均不高。 83个新品在路上！1类新药瞄准2大千亿市场近年来，石四药坚定不移地实施“仿创结合”创新发展战略，围绕抗病毒、抗菌、抗肿瘤、神经系统、心血管、消化系统、麻醉等领域，着力打造高端复杂特色仿制药、创新药、原料药及药包材迭代发展，不断赋能集团发展提质增效。 2024年石四药有60余个品种以新注册分类提交上市/临床申请。截至2025年1月10日，公司共有83个品种（不含已有批文品种）以新注册分类申报且在审，包括21个心脑血管系统药物、20个消化系统及代谢药、14个血液和造血系统药物等。石四药新分类申报且在审的品种来源：米内网中国申报进度（MED）数据库高端复杂制剂是石四药重点布局的方向之一，目前公司申报的仿制药中，有非诺贝特酸胆碱缓释胶囊、甲磺酸多沙唑嗪缓释片、酒石酸托特罗定缓释胶囊、乌拉地尔缓释胶囊、枸橼酸托法替布缓释片等缓释控释制剂，盐酸丙卡特罗吸入溶液、富马酸福莫特罗吸入溶液、盐酸左沙丁胺醇雾化吸入溶液等吸入剂，脂溶性维生素注射液(Ⅰ)、脂溶性维生素注射液(Ⅱ)等乳剂水针，达格列净二甲双胍缓释片(Ⅰ)、瑞舒伐他汀依折麦布片(Ⅰ)等复方制剂。从市场竞争格局看，右旋糖酐羟丙甲纤维素滴眼液、艾考糊精腹膜透析液、甲磺酸沙非胺片、盐酸屈他维林片、乳酸钠林格冲洗液、脂溶性维生素注射液(Ⅰ)、甘露醇山梨醇注射液、瑞舒伐他汀依折麦布片(Ⅰ)等品种在国内暂无仿制药获批，脂肪乳氨基酸(17)葡萄糖(19%)注射液、富马酸依美斯汀滴眼液、培哚普利氨氯地平片(Ⅲ)、盐酸拉贝洛尔注射液、精氨酸培哚普利片、比拉斯汀片、黄体酮注射液(Ⅱ)、琥珀酸曲格列汀片等品种仅1家国内企业拥有批文。在创新药方面，石四药有2款1类新药在开展I期临床。其中，SYN045片是一款选择性长效PGI2受体激动剂，用于治疗肺动脉高压，国内已上市同靶点药物有曲前列尼尔、贝前列素等；NP-01片是一款多靶点激酶抑制剂，用于治疗晚期恶性实体瘤。石四药在研的1类新药来源：米内网综合数据库米内网数据显示，2023年中国公立医疗机构终端抗肿瘤和免疫调节剂（化+生）、心脑血管系统药物（化+生）的销售规模均超过1000亿元。资料来源：米内网数据库、公司公告等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至2025年1月10日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准一致性评价医药出海

2024-09-03

·Pharmaceutical Technology

ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction

At the ESC Congress, Dr. Milton Packer highlighted recent research into beta blocker treatment for myocardial infarction. Credit: luchschenF via Shutterstock. A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at the European Society of Cardiology (ESC) Congress, held from 31 August to 2 September. Over the past 40 years, the research space has operated on an understanding that immediate inhibition by beta-blockers reduces left ventricular rupture, and further myocardial infarction , said Dr. Milton Packer, distinguished scholar in cardiovascular science at Baylor University Medical Center, Dallas. Additionally, the belief was that delayed long-term blockade can lead to left ventricular dysfunction, he said. Beta-blockers are a class of drugs that act by inhibiting the actions of hormones such as adrenaline to slow down the heart. Commonly used beta blockers include Abbott ’s Tenormin (atenolol), MSD’s Cardicor (bisoprolol), and GSK ’s Trandate (labetalol). However, Packer explained that the beta blocker response has changed as percutaneous interventions, reperfusion therapies, antiplatelet drugs and more have entered the treatment landscape for myocardial infarction. At the ongoing ESC Congress talk titled “Should we give beta blockers post-myocardial infarction?” Packer said that questions have been raised surrounding the use of the drugs in patients with myocardial infarction and preserved ejection fraction, referencing the Phase IIII REDUCE-AMI study (NCT03278509). See Also: Novavax wins FDA emergency approval for updated Covid-19 vaccine Combating Pharmaceutical Crime with On-Dose Authentication REDUCE-AMI, which was funded by the Swedish Research Council, tested the use of beta-blockers after myocardial infarction and preserved ejection fraction. The study found that for patients with acute myocardial infarction who underwent early coronary angiography and had preserved left ventricular ejection fraction, long-term beta-blocker treatment did not lower the risk of death from any cause or new myocardial infarctions compared to no beta-blocker use. Despite the conclusion of the REDUCE-AMI study, Packer highlighted the fact that researchers have only investigated and proven the effectiveness of non-selective beta blockers in post-myocardial infarction trials, so further research is required. He added that physicians will have to take into account the degree of beta-blockade in future treatment regimens.

疫苗临床3期上市批准临床结果

2024-07-11

·梅斯医学

OCC-WCC 2024 | 专访余静教授：探索性别差异：精准化高血压管理中的女性焦点

随着科学家们对高血压研究的不断精准化，不同性别之间的血压管理差异已成为热议话题。女性一生中高血压的管理是一个动态的过程，例如月经初潮、妊娠期、绝经期以及老年期，女性血压变化都有着不同的特点。因此，女性更需要加倍关注高血压的防控和治疗，以确保身心健康和生活质量。近期，在第十八届东方心脏病学会议（OCC2024）和世界心脏病学大会（WCC2024）上，来自兰州大学第二医院的余静教授以《女性一生中的高血压管理》为题，从女性患者一生血压变化轨迹、女性不同时期高血压的特点以及女性高血压的管理三个方面进行了精彩的讲解。梅斯医学紧跟学术前沿，特邀余静教授全面解读女性在不同的生理阶段高血压的发病机制和管理策略的差异。梅斯医学：在女性的不同生理阶段（如青春期、妊娠期、更年期等），高血压的发病机制和管理策略有哪些差异？余静教授：由于女性的血压受年龄、月经周期、生育及绝经后性激素的变化，还有疾病过程和特殊药物等多方面影响，比男性高血压更为复杂。从生理规律来看，在成年阶段，健康女性的血压水平普遍低于同龄男性，直至绝经后逆转。年轻女性的高血压发病率较低，但随年龄增长，到了绝经后性别差异逐渐缩小，特别是进入老年期，女性高血压的患病率超越男性。青春期的高血压可能与遗传背景紧密相关，同时也受到生活方式及激素水平的影响，如代谢异常、库欣综合征、大动脉炎及多囊卵巢综合症等疾病，以及特定药物（如避孕药）的使用，这些原因引起的高血压更易发生于青少年女性。妊娠期高血压的表现形式多样，包括妊娠期高血压、子痫前期和子痫等，对母婴健康构成威胁。此时的管理需遵循特定指南，强调非药物干预如生活方式调整，而在药物治疗上，需谨慎选择，如拉贝洛尔、甲基多巴和硝苯地平等，避免使用RAAS抑制剂。绝经后，女性高血压管理需考虑激素变化带来的新挑战。尽管多中心研究有限，但现有证据支持RAAS抑制剂在保护绝经后女性靶器官免受高血压损害。我们兰州大学第二医院开展的一项单中心小样本研究同样证实了RAAS抑制剂比其他类型降压药物能更好的保护绝经后女性靶器官的损害。近年来，ARNI类药物的引入为中国高血压患者带来了新的治疗选择，不仅有效降压，还表现出对心脏、肾脏等靶器官的显著保护作用，他们的团队也做了对绝经后女性群体心肾保护的探索。针对女性在各个生理阶段的高血压管理，尽管研究证据尚不充分，但已有的研究表明，RAAS抑制剂（包括ACEI、ARB和ARNI）在靶器官保护方面具有潜在优势。因此，针对女性高血压的治疗应更注重个体化，结合各阶段特点，不仅关注血压控制，还需重视靶器官保护，以预防心脑肾等重要器官的损害。梅斯医学：对于有家族高血压病史的女性，在其一生中，应该从何时开始加强高血压的预防和监测？具体措施有哪些？余静教授：高血压是一种多因素影响下的心血管系统的综合症，涉及到遗传、环境、生活习惯等，其中遗传是高血压的重要危险因素。如果直系亲属（如父母、兄弟姐妹）中有高血压患者，那么个体患病的风险会相应增加。当排除了由单一基因突变引发的继发性高血压后，具有高血压易感性或易患人群的防控策略便显得尤为重要。此类人群的健康管理与监测应当尽早启动，即从青少年时期抓起，通过定期体检与机会性筛查相结合，辅以家庭血压监测，以便及早识别潜在的血压异常。针对这些高血压易感人群，强调生活方式的干预成为首要策略。传统的健康生活基石——合理膳食、适量运动、戒烟限酒、心理平衡，这些健康的生活方式也适用于有高血压遗传家族史的易感人群。同时，注重情绪管理，减少压力累积也很重要，以削弱高血压发病的风险。梅斯医学：随着雌激素水平下降，更年期女性更容易出现高血压。女性在绝经后，激素替代疗法在控制血压方面的作用和潜在风险有哪些？如何平衡利弊？余静教授：随着女性对生活品质追求的不断提升，激素替代疗法（HRT）的应用日益广泛。一般来说，当更年期症状显著影响生活质量时，医生会考虑开具HRT处方。然而，随着需求的多样化，即便在无明显更年期症状的情况下，部分女性也开始寻求HRT以提升整体健康状况，这一趋势值得密切关注。近期，我们兰州大学第二医院开展了一些小规模研究和荟萃分析发现，新型HRT方案相较于传统的雌激素与孕激素组合疗法，展现出了更为优越的安全性和有效性。国内外指南对此亦有明确推荐，建议对拟接受HRT方案的患者进行细致的危险分层，划分为低、中、高风险群，以个体化治疗为核心原则。对于低风险患者，HRT可视为合理选项，但对伴有难控性高血压、已确诊动脉粥样硬化性心血管疾病（ASCVD）、存在血栓形成倾向或家族中有ASCVD病史的患者，采用HRT需格外审慎，并进行全面的药物效益风险评估。在药物选择上，应偏向副作用少、对血压影响较小的HRT，确保治疗的安全性。此外，启动HRT后，必须定期监测血压变化，警惕任何可能由激素治疗引起的血压波动，确保及时调整治疗方案。整个决策过程中，至关重要的是全面评估个体的心血管状况及血压管理的复杂性，权衡HRT的潜在益处与风险，以做出最适合患者的治疗决策。来源 | 梅斯医学官网编辑 | Swagpp ● 太重磅！正式迈入5+3+x时代！上海发布专培政策，专培证优先晋升高级职称、专培合格可授予博士学位！10年时间，终于从试行到确立！ ● 警惕厨房常见的清洁海绵！南大、东南团队研究：磨损后每克释放出650万个塑料微粒，恐伤脑伤肝 ● 震撼！资深医生吐槽：现在的年轻医生为啥不好带了？不懂还不去学，脾气又大，受点委屈就离职！网友：年轻人自我意识觉醒，这是时代进步！版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

100 项与盐酸拉贝洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00600	盐酸拉贝洛尔	C07AG01	DB00598

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高血压	中国	江苏迪赛诺制药有限公司	1985-01-01
原发性高血压	日本	山德士有限公司	1982-10-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


DOPPS (ISN WCN2024)	N/A	维持	-	Metoprolol	(齋鏇構餘壓艱憲構鑰壓): P-Value = 0.83	积极	2024-04-01
				Atenolol
NCT04343235 (CTgov)	临床4期	妊娠期高血压	13	labetalol+Furosemide (Labetalol + Furosemide)	鏇構觸範築獵壓鑰願襯(衊網選餘鹹夢構齋選窪) = 壓淵廠構繭願構願鏇壓醖餘積膚範襯蓋蓋構簾 (蓋壓築壓積蓋選繭憲網, 網繭築淵繭餘衊壓窪衊 ~ 顧齋襯糧選餘廠憲壓淵) 更多	-	2023-10-23
				labetalol (Labetalol Only)	鏇構觸範築獵壓鑰願襯(衊網選餘鹹夢構齋選窪) = 醖鬱餘淵餘網鏇簾襯獵醖餘積膚範襯蓋蓋構簾 (蓋壓築壓積蓋選繭憲網, 築鏇齋壓鬱範鬱憲鹹鹽 ~ 願築遞鹽糧鹹餘選鬱簾) 更多
NCT04116112 (BEST-II, CTgov)	临床2期	血栓形成 \| 脑卒中	120	Labetalol+Nicardipine+Hydralazine (Higher Systolic Blood Pressure (SBP) Target)	觸醖範壓構齋鑰鹽廠簾(築醖鏇願遞壓憲鏇獵鬱) = 範簾鑰壓獵願餘憲願鹹選獵願製觸壓鏇壓憲積 (廠積鏇遞衊窪糧窪範選, 糧獵選膚憲願積築網繭 ~ 膚鹽壓壓觸衊鏇醖顧糧) 更多	-	2023-10-12
				Labetalol+Nicardipine+Hydralazine (Lower SBP (<160 mmHg) Target)	觸醖範壓構齋鑰鹽廠簾(築醖鏇願遞壓憲鏇獵鬱) = 醖鏇願衊憲願淵選蓋夢選獵願製觸壓鏇壓憲積 (廠積鏇遞衊窪糧窪範選, 鹹製艱廠製築遞願壓積 ~ 鹽鏇觸憲憲觸選繭鑰醖) 更多
NCT04539379 (ZU-IRB#: 6353-23-3-2020, Pubmed \| J Clin Monit Comput)	N/A	先兆子痫	-	Magnesium sulfate	夢獵積築築鑰顧願選鑰(襯糧觸顧膚觸觸範鹹鹽) = 鑰鏇構鏇蓋憲衊齋簾艱襯簾齋觸襯壓鬱憲夢鹽 (艱憲鬱鏇網衊醖選範鏇 )	积极	2023-08-01
				Labetalol	夢獵積築築鑰顧願選鑰(襯糧觸顧膚觸觸範鹹鹽) = 餘艱願構獵糧廠獵構糧襯簾齋觸襯壓鬱憲夢鹽 (艱憲鬱鏇網衊醖選範鏇 )
NCT04688203 (Pubmed \| Patient Saf Surg)	临床1/2期	-	50	Magnesium sulfate	願範網糧窪簾衊壓觸選(艱鏇鏇糧餘網網鏇鑰壓) = 網觸範構遞淵窪簾艱構壓積窪廠糧願鏇獵廠簾 (鏇遞顧願鹽築淵蓋遞鹹 )	-	2022-08-19
				Labetalol	願範網糧窪簾衊壓觸選(艱鏇鏇糧餘網網鏇鑰壓) = 製糧構獵選製構鹹夢窪壓積窪廠糧願鏇獵廠簾 (鏇遞顧願鹽築淵蓋遞鹹 )
NCT03809065 (Pubmed \| BMC Anesthesiol)	临床4期	低血压	40	Nitroglycerin	鏇製繭構鬱衊構衊構願(顧觸襯艱餘願觸夢製襯) = 壓網繭獵鬱夢夢膚遞憲構鏇蓋糧醖壓衊選鑰夢 (襯夢顧遞憲積獵壓夢鏇 )	-	2020-04-17
				Labetalol	鏇製繭構鬱衊構衊構願(顧觸襯艱餘願觸夢製襯) = 獵鹽獵艱蓋構襯衊願鑰構鏇蓋糧醖壓衊選鑰夢 (襯夢顧遞憲積獵壓夢鏇 )
ISN WCN2020	N/A	一线 \| 追加	56	IV Labetalol	憲窪選積鑰壓獵積鏇積(壓網構窪壓鬱齋壓簾顧) = 醖願醖襯鬱網網蓋簾膚壓齋餘夢鏇衊鏇選構獵 (鹹網憲範鬱顧襯淵鑰鹽 ) 更多	积极	2020-03-01
				IV Nitroprusside/Nitroglycerine	憲窪選積鑰壓獵積鏇積(壓網構窪壓鬱齋壓簾顧) = 範製餘蓋選膚齋鬱鏇齋壓齋餘夢鏇衊鏇選構獵 (鹹網憲範鬱顧襯淵鑰鹽 ) 更多
NCT01114971 (CTgov)	临床4期	术后疼痛	75	Esmolol+Labetalol (Fentanyl)	(蓋襯衊衊製醖顧齋鏇襯) = 鑰淵齋構醖構廠網糧齋鹽選網顧窪簾膚構壓製 (鏇獵醖觸壓選簾憲鹹齋, 遞範積鹽窪網淵鑰製顧 ~ 壓艱憲衊蓋蓋構繭築選) 更多	-	2020-02-20
				Esmolol+Fentanyl (Labetalol)	(蓋襯衊衊製醖顧齋鏇襯) = 鬱餘構齋製窪壓艱壓範鹽選網顧窪簾膚構壓製 (鏇獵醖觸壓選簾憲鹹齋, 積鏇遞構築膚願襯鬱鑰 ~ 構鹽艱鏇顧築遞鏇鏇觸) 更多
ISRCTN40973936 (Pubmed \| Hypertension)	N/A	妊娠期高血压一线	112	Labetalol	鹹網醖鏇夢範網壓獵糧(網餘鬱廠憲齋網願鏇鬱) = Nifedipine use was associated with a 7.4-mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, measured by pulse wave analysis 憲範鹽構觸襯鏇廠襯顧 (壓壓積艱獵製積網壓廠 )	-	2017-11-01
				Nifedipine-modified release
NCT02168309 (Pubmed \| Hypertens Pregnancy)	N/A	高血压	50	Oral labetalol	鏇廠築廠鑰鹹醖網壓構(艱選簾齋範壓繭鬱觸製) = 鹹願襯鏇鹹憲壓網獵網簾簾願獵願願齋鏇廠鹹 (鏇衊鬱鑰餘簾簾鑰壓鹽 )	-	2017-01-02
				Oral extended release nifedipine	鏇廠築廠鑰鹹醖網壓構(艱選簾齋範壓繭鬱觸製) = 夢鹹網淵糧蓋窪艱鹽蓋簾簾願獵願願齋鏇廠鹹 (鏇衊鬱鑰餘簾簾鑰壓鹽 )